Drug intelligence / Profile preview

ParaCel

Development stage: Unknown
Lead developer: Glaukos
Modality: Small Molecules
Administration: Ophthalmic

Overview

ParaCel is a proprietary riboflavin formulation developed by Dr. Roberto Pinelli for epithelium-on (epi-on) corneal collagen cross-linking. It is used to treat keratoconus, a condition characterized by progressive thinning and weakening of the cornea. Avedro acquired the intellectual property rights to ParaCel from the Switzerland Eye Research Institute in 2011, aiming to provide a safer, faster, and less invasive treatment option for keratoconus by avoiding the pain and risks associated with epithelium removal.

Brand names: ParaCel

Targets

COL1A2 (Type I collagen alpha-2 chain)

Beyond the preview

Go deeper on ParaCel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ParaCel.

Explore the full profile